Sun Pharma has moved to bolster its board with the appointment of an independent director, Satyavati Berera. The board approved her appointment for a five-year term, subject to shareholders’ approval. If the shareholders back the move, Berera would join the board as an independent voice to augment governance, oversight and strategic decision-making.
Berera comes to Sun Pharma with a 40-year-plus track record in finance, operations and governance. She is the former Chief Operating Officer of PwC India, a Fellow member of the ICAI, and a chartered accountant who rose through PwC to leadership roles including partner, head of consulting and managing partner for the firm’s northern region before becoming COO in 2016. She retired in 2023 after a career spanning assurance, consulting and governance, risk and compliance.
Industry observers say the appointment underscores Sun Pharma’s commitment to independent governance and depth of expertise as it navigates a complex and highly regulated sector. Berera’s experience across finance, technology and risk management is expected to enrich the board’s oversight and strategic deliberations.
The appointment is to take effect from the date of shareholders’ approval by postal ballot, and is designed to preserve the balance and diversity of the board while reinforcing its governance capability.